Chaoyang Perpetual Data shows that as of August 10, 7 private equity firms with 10 billion yuan entered the top ten circulating shareholders of 34 listed companies, including 7 new ones in the second quarter, increasing their holdings of 11, and reducing their holdings of 4 compa

China Times (www.chinatimes.net.cn) reporter Song Jie and Chen Feng Beijing report

As the semi-annual reports of listed companies were disclosed one after another, the heavy holdings of 10 billion private equity firms in the second quarter were also exposed. Chaoyang Perpetual Data shows that as of August 10, 7 private equity firms with 10 billion yuan entered the top ten circulating shareholders of 34 listed companies, including 7 new ones in the second quarter, increasing their holdings of 11, and reducing their holdings of 4 companies to varying degrees.

Among them, Gaoyi assets Deng Xiaofeng increases holdings Huadong Pharmaceutical and Lianchuang Electronics. Another big name Feng Liu sticks to Lingrui Pharmaceutical , significantly reducing holdings Rongzhirixin; Jinglin Asset Jiang Tong maintains Jinshi Resources; Hillhouse Lingren Investment sticks to Lizhu Group .

A private equity person with a 10 billion yuan told the reporter of " China Times " that there are many factors that private equity products appear among the top ten circulating shareholders of listed companies. They are not necessarily heavily held stocks of private equity products, and their impact on net value is not exactly the same. Moreover, the interim reports of listed companies are lagging behind, and investors cannot blindly refer to them.

10 billion private equity has newly added 7 stocks

17 listed companies that received 10 billion private equity for the first time in the second quarter are all small-cap stocks with a market value of less than 30 billion yuan.

Last year, the two products under Alluvial Asset, the 10 billion private equity champion, were newly added to the top ten shareholders of the new energy vehicle concept stock Kelike (002782.SZ) in the second quarter, with a total of holdings of holdings of , and the market value as of the end of the second quarter was 72.95 million yuan.

Kelik's interim report shows that the company achieved revenue of 1.038 billion yuan in the first half of the year, an increase of 39.43% year-on-year; net profit of 61.7225 million yuan, an increase of 42.65% year-on-year.

At the same time, another product under Alluvial Assets has become the ninth largest circulating shareholder of Yinbang Co., Ltd. (300337.SZ), holding 3.3408 million shares and a market value of approximately 36.85 million yuan.

Yinbang Co., Ltd.'s main products are aluminum heat transfer materials, multi- metal composite materials, , aluminum-steel composite materials and aluminum alloy composite protective materials, etc., which are mainly used in transportation, engineering machinery, electricity, consumer electronics, home appliances and other fields. The announcement shows that the company achieved revenue of 1.907 billion yuan in the first half of the year, an increase of 34.57% year-on-year; net profit of 90.5 million yuan, an increase of 369.73% year-on-year.

Since April 27, the stock prices of both companies have rebounded strongly, with gains reaching 168% and 198% respectively as of the close of August 10.

Xuanyuan Investment also became the tenth largest circulating shareholder of Yingweike (002837.SZ) and Weisheng Information (688100.SH) in the second quarter, holding 4.4564 million shares and 2.11 million shares respectively. Since the end of April, Invik's stock price has doubled, and Visco Information has risen by more than 50%.

Xiangju Capital has built a position of 31 million yuan for the electronic testing industry. The company's stock price has doubled since it reached a low point in April.

Ningquan Asset, initiated by Yang Dong, a well-known private equity tycoon, has become the largest circulating shareholder seat of Yuanli Co., Ltd. (300174.SZ), holding 2.5609 million shares at the end of the period, with a market value of 39.4884 million yuan. Since April 27, the stock price has risen 71%.

Since the rebound of the market , Longpan Technology (603906.SH), a newly bought new investment in Yingshui Investment, has the least gained, with only 19%. Yingshui Investment held 3.2252 million shares in the second quarter, with a market value of 119 million yuan.

Love Moutai has been promoted to a 10 billion private equity

Kweichow Moutai (600519.SH) is the only stock that has been favored by two 10 billion private equity , and has once again received increased holdings from the mysterious 10 billion private equity treasury Jinhui Rongsheng and Ruifeng Huibang Assets.

Tonglian data shows that Jinhui Rongsheng No. 3 Fund became the top ten circulating shareholders of Moutai in its interim report in 2019. At that time, it held 3.4134 million shares and a market value of 3.359 billion yuan. Since then, the overall position has been continuously increased, and the position was increased by more than 2 billion yuan in the second quarter of this year. Ruifeng Huibang No. 3 Fund entered the top ten circulating shareholders in the fourth quarter of 2018. The market value of its holdings at that time was 2.1 billion yuan, and it has increased its holdings to 8.7 billion yuan.

As Moutai's stock price continues to rise, the two private equity firms have also successfully entered the 10 billion club. In a few years, the total floating profits of the two funds may exceed 10 billion yuan.

Previously, a reporter from the China Times contacted two private equity firms many times about their investment philosophy, but no reply was received.

Jinglin Fengshou No. 3 managed by Jiang Tong continued to hold 0.65% of Jinshi Resources (603505.SH) shares in the second quarter. This is the third quarter it has been held since it bought and became the top ten shareholders of the company in the fourth quarter of last year. This year, Jinshi Resources' stock price has risen 57%.

The second-level private equity fund Lingren, a subsidiary of Hillhouse Capital, also continued to stick to the top ten circulating shareholders of Lizhuang Group (000513.SZ) for the third quarter. This is the only heavily held stock exposed by Lingren Private Equity, but its share price has fallen by 19% this year.

Lizhu Group mainly engages in chemical preparations, raw materials and intermediates, Chinese patent medicines, vaccines, diagnostic reagents and equipment. In the first half of this year, the company's revenue was 6.303 billion yuan, a slight increase of 1.08% year-on-year; net profit was 1.018 billion yuan, a 4.23% year-on-year decrease.

Panjing Investment increased its stake in Lanxiao Technology (300487.SZ), adhered to the stake in Oppein (603208.SH), and reduced its stake in Sanxiang New Materials (603663.SH).

Gao Yi appears in 6 shares

Gao Yi Asset currently appears in the top ten circulating shareholders of 6 listed companies. Among them, Xiaofeng managed by Deng Xiaofeng sent a letter to Xiaofeng Hongyuan and Xiaofeng Hongyuan increased its holdings in East China Pharmaceutical (000963.SZ) with 1.7969 million shares, currently holdings of 15.1731 million shares, with a market value of 684 million yuan at the end of the quarter.

Huadong Medicine entered the dual tracks of medical beauty and innovative drugs. The semi-annual report disclosed on the evening of August 9 showed that the company achieved operating income of 18.198 billion yuan in the first half of the year, a year-on-year increase of 5.93%; net profit of 1.341 billion yuan, a year-on-year increase of 3.09%. Since the company's stock price rebounded with the market on April 27, it has risen by 49%.

The above two funds also increased their holdings in Lianchuang Electronics (300343.SZ) in the second quarter, holding 27.0188 million shares, with a market value of 414 million yuan.

Lianchuang Co., Ltd. mainly focuses on the businesses of fluorine new materials and polyurethane , and is the upstream of the new energy industry chain. In the first half of the year, the company achieved operating income of 1.194 billion yuan, a year-on-year increase of 63.02%; net profit was 673 million yuan, a year-on-year increase of 1325.58%. The company's stock price started a rebound since April 27, and as of August 11, the cumulative stock price rose by more than 63%.

Linshan No. 1 Yuanwang Fund, which Feng Liu is in charge, is still the second largest shareholder of Lingrui Pharmaceutical (600285.SH), with a market value of approximately RMB 338 million. At the same time, he also reduced his holdings of positions in , which is nearly 80% of his holdings.

Lingrui Pharmaceutical is an enterprise with the main business of pharmaceutical production and operation. It is also the first listed enterprise in the rubber ointment pharmaceutical industry in the country. It has more than 100 products such as rubber ointment, tablets, capsules, and injections.

htmlOn August 10, Lingrui Pharmaceutical released its semi-annual report, with the company achieving revenue of 1.503 billion yuan, a year-on-year increase of 10.86%; net profit of 271 million yuan, a year-on-year increase of 23.15%.

Zhuo Liwei reduced his holdings of 4.4 million shares of Jiuli Special Materials (002318.SZ), currently holds 15.33 million shares, ranking the sixth largest circulating shareholder, with a market value of 245 million yuan. At the same time, he also significantly increased his holdings in Huafeng Chemical (002064.SZ), becoming its seventh largest shareholder, holding 28.9501 million shares, with a market value of 244 million yuan.

Editor: Yan Hui Editor-in-chief: Xia Shencha